Pneumococcal Vaccines (PV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Pneumococcal Vaccines (PV) Marketed and Pipeline Drugs Report Overview

Pneumococcal Vaccines (PV) infections can broadly be classified into one of two types. In non-invasive pneumococcal disease, the infection does not penetrate normally sterile sites, such as the blood or cerebrospinal fluid (CSF). Infections tend to be mild in severity and can often resolve without treatment. Since there are several types of pneumococcal disease, symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion.

The PV marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in PV therapeutics.

PV Marketed Vaccines

The PV market is currently dominated by two players (Pfizer and Merck & Co) across the US, EU, Japan, Australia, and South Korea. Merck & Co’s Pneumovax 23 is a polysaccharide sub-unit vaccine that was first approved in 1983 and is one of the major brands in the PV market that is approved for children older than age two years, besides being used for adults in the PV landscape. The current state of the PV market portfolio is marked by a clear line between the leading product with maximum sales in market, Pfizer’s Prevnar 13, and the trailing product, Merck & Co’s Pneumovax 23 and Vaxneuvance.

PV Pipeline Drugs Segmentation by Routes of Administration

The key routes of administration for PV pipeline drugs are injection, inhalational, and oral. In 2023, of all the PV pipeline vaccines, the most common route of administration is injectables.

PV Pipeline Drugs Analysis by RoA, 2023 (%)

For more RoA insights into the PV pipeline drugs market, download a free report sample

PV Clinical Trials Segmentation by Region

In the past 10 years, the highest number of single-country trials for PV were conducted in the Asia-Pacific region, followed by North America and Europe. However, the number of multinational trials  for PV was highest in Europe , followed by Asia-pacific and North America.

Clinical Trials in PV by Region, 2023 (%)

For more insights on the clinical trials in PV by region, download a free sample report

PV Clinical Trials – Top Countries for Trial Sites

Some of the key countries in the clinical trial sites in PV are the US, Japan, South Korea, India, China, Poland, Spain, Australia, Canada, Germany, France, Finland, United Kingdom, Belgium, Sweden, Hungary, Chile, Czech Republic, Taiwan, and New Zealand. In 2023, the US dominated the total count of clinical trials in PV.

Clinical Trials in PV by Country, 2023 (%)

For more insights on the clinical trials in PV by country, download a free sample report

Top Sponsors in the PV Marketed and Pipeline Drugs Market

Some of the top sponsors in the PV marketed and pipeline drugs market are Pfizer Inc, Merck & Co Inc, Sinovac Biotech Ltd, Biological E Ltd, Affinivax Inc, PATH, Walvax Biotechnology Co Ltd, Vaxcyte Inc among others. In 2023, Pfizer leads among the sponsors for completed trials in PV (22 trials). In terms of ongoing trials, Merck & Co has the highest number of trials (seven trials).

Segments Covered in the Report

PV Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

• Injection
• Inhalational
• Oral

Scope

GlobalData’s PV Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the PV market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PV market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.